FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050870116> ?p ?o ?g. }

• W2050870116 endingPage "1072" @default.
• W2050870116 startingPage "1067" @default.
• W2050870116 abstract "Objective The aim of this study was to investigate the outcome of overlap/switch to adefovir dipivoxil (ADV) monotherapy for chronic hepatitis B (CHB) patients with lamivudine (LAM)-resistant HBV, who responded to LAM plus ADV combination therapy. Methods In 29 of 35 LAM-resistant CHB patients, serum HBV-DNA levels decreased to <3.7 log genome equivalent (LGE)/mL at 12 months after LAM plus ADV combination therapy, defined as complete virological response (CVR). The 29 CVR patients were randomly allocated to continuation of combination therapy or switch to ADV monotherapy within 12 months. The cumulative rates of sustained CVR were compared between the two groups. Results The follow-up duration after randomization was 19.3-36.7 months (median, 28.2 months) for the combination group and 21.0-36.4 months (29.0 months) for the overlap/switch group. The cumulative rate of sustained CVR during the follow-up period was 100% in all patients of both groups. The total medical expenses during follow-up after randomization were median US$20,949 for the combination group and US$16,107 for the overlap/switch group (p=0.012). Overlap/switch to ADV monotherapy sufficiently repressed the replication of LAM-resistant mutants without the development of ADV-resistant mutants. The rate of sustained CVR was not influenced by treatment regimen (continuation of combination therapy or switching to ADV monotherapy), the duration of the overlap period, or patient and virological characteristics. Conclusion In LAM-resistant CHB patients who achieved CVR to LAM plus ADV combination therapy, CVR was maintained after overlap/switch to ADV monotherapy, suggesting that it could be a useful regimen for such patients." @default.
• W2050870116 created "2016-06-24" @default.
• W2050870116 creator A5000850011 @default.
• W2050870116 creator A5012016072 @default.
• W2050870116 creator A5012836470 @default.
• W2050870116 creator A5020671675 @default.
• W2050870116 creator A5051763064 @default.
• W2050870116 creator A5065317007 @default.
• W2050870116 creator A5074025359 @default.
• W2050870116 creator A5086577428 @default.
• W2050870116 creator A5086743926 @default.
• W2050870116 date "2010-01-01" @default.
• W2050870116 modified "2023-09-28" @default.
• W2050870116 title "Overlap/Switch to Adefovir Monotherapy for Lamivudine-resistant Patients Who Responded to Combination Therapy: A Pilot Controlled Study" @default.
• W2050870116 cites W1964242359 @default.
• W2050870116 cites W1970657877 @default.
• W2050870116 cites W1985577568 @default.
• W2050870116 cites W2023509812 @default.
• W2050870116 cites W2041012817 @default.
• W2050870116 cites W2045347800 @default.
• W2050870116 cites W2058376942 @default.
• W2050870116 cites W2060620119 @default.
• W2050870116 cites W2071337588 @default.
• W2050870116 cites W2076506726 @default.
• W2050870116 cites W2085990351 @default.
• W2050870116 cites W2116148860 @default.
• W2050870116 cites W2120667564 @default.
• W2050870116 cites W2142557452 @default.
• W2050870116 cites W2161280033 @default.
• W2050870116 cites W2169342982 @default.
• W2050870116 cites W2338794667 @default.
• W2050870116 cites W2393327590 @default.
• W2050870116 doi "https://doi.org/10.2169/internalmedicine.49.3342" @default.
• W2050870116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20558919" @default.
• W2050870116 hasPublicationYear "2010" @default.
• W2050870116 type Work @default.
• W2050870116 sameAs 2050870116 @default.
• W2050870116 citedByCount "4" @default.
• W2050870116 countsByYear W20508701162012 @default.
• W2050870116 countsByYear W20508701162014 @default.
• W2050870116 countsByYear W20508701162016 @default.
• W2050870116 crossrefType "journal-article" @default.
• W2050870116 hasAuthorship W2050870116A5000850011 @default.
• W2050870116 hasAuthorship W2050870116A5012016072 @default.
• W2050870116 hasAuthorship W2050870116A5012836470 @default.
• W2050870116 hasAuthorship W2050870116A5020671675 @default.
• W2050870116 hasAuthorship W2050870116A5051763064 @default.
• W2050870116 hasAuthorship W2050870116A5065317007 @default.
• W2050870116 hasAuthorship W2050870116A5074025359 @default.
• W2050870116 hasAuthorship W2050870116A5086577428 @default.
• W2050870116 hasAuthorship W2050870116A5086743926 @default.
• W2050870116 hasBestOaLocation W20508701161 @default.
• W2050870116 hasConcept C126322002 @default.
• W2050870116 hasConcept C168563851 @default.
• W2050870116 hasConcept C203014093 @default.
• W2050870116 hasConcept C204243189 @default.
• W2050870116 hasConcept C2522874641 @default.
• W2050870116 hasConcept C2776999253 @default.
• W2050870116 hasConcept C2777382497 @default.
• W2050870116 hasConcept C2777869810 @default.
• W2050870116 hasConcept C2779517838 @default.
• W2050870116 hasConcept C2781413609 @default.
• W2050870116 hasConcept C3020491458 @default.
• W2050870116 hasConcept C71924100 @default.
• W2050870116 hasConcept C90924648 @default.
• W2050870116 hasConceptScore W2050870116C126322002 @default.
• W2050870116 hasConceptScore W2050870116C168563851 @default.
• W2050870116 hasConceptScore W2050870116C203014093 @default.
• W2050870116 hasConceptScore W2050870116C204243189 @default.
• W2050870116 hasConceptScore W2050870116C2522874641 @default.
• W2050870116 hasConceptScore W2050870116C2776999253 @default.
• W2050870116 hasConceptScore W2050870116C2777382497 @default.
• W2050870116 hasConceptScore W2050870116C2777869810 @default.
• W2050870116 hasConceptScore W2050870116C2779517838 @default.
• W2050870116 hasConceptScore W2050870116C2781413609 @default.
• W2050870116 hasConceptScore W2050870116C3020491458 @default.
• W2050870116 hasConceptScore W2050870116C71924100 @default.
• W2050870116 hasConceptScore W2050870116C90924648 @default.
• W2050870116 hasIssue "12" @default.
• W2050870116 hasLocation W20508701161 @default.
• W2050870116 hasLocation W20508701162 @default.
• W2050870116 hasOpenAccess W2050870116 @default.
• W2050870116 hasPrimaryLocation W20508701161 @default.
• W2050870116 hasRelatedWork W1871526758 @default.
• W2050870116 hasRelatedWork W1969055524 @default.
• W2050870116 hasRelatedWork W1980627494 @default.
• W2050870116 hasRelatedWork W1988549760 @default.
• W2050870116 hasRelatedWork W1992719847 @default.
• W2050870116 hasRelatedWork W2005021102 @default.
• W2050870116 hasRelatedWork W2023509812 @default.
• W2050870116 hasRelatedWork W2027020880 @default.
• W2050870116 hasRelatedWork W2029549391 @default.
• W2050870116 hasRelatedWork W2089873940 @default.
• W2050870116 hasRelatedWork W2121067273 @default.
• W2050870116 hasRelatedWork W2186105323 @default.
• W2050870116 hasRelatedWork W2355172396 @default.
• W2050870116 hasRelatedWork W2377177862 @default.
• W2050870116 hasRelatedWork W2389388769 @default.

• next